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Abstract
Background: To evaluate diagnostic and long-term prognostic values of hFABP compared to NT-proBNP and
troponin I (TnI) in patients presenting to the emergency department (ED) suspected of acute heart failure (AHF).
Methods: 401 patients with acute dyspnea or peripheral edema, 122 suffering from AHF, were prospectively
enrolled and followed up to 5 years. hFABP combined with NT-proBNP versus NT-proBNP alone was tested for AHF
diagnosis. Prognostic value of hFABP versus TnI was evaluated in models predicting all-cause mortality (ACM) and
AHF related rehospitalization (AHF-RH) at 1 and 5 years, including 11 conventional risk factors plus NT-proBNP.
Results: Additional hFABP measurements improved diagnostic specificity and positive predictive value (PPV) of sole
NT-proBNP testing at the cutoff <300 ng/l to “rule out” AHF. Highest hFABP levels (4th quartile) were associated
with increased ACM (hazard ratios (HR): 2.1–2.5; p = 0.04) and AHF-RH risk at 5 years (HR 2.8–8.3, p = 0.001). ACM was
better characterized in prognostic models including TnI, whereas AHF-RH was better characterized in prognostic
models including hFABP. Cox analyses revealed a 2 % increase of ACM risk and 3–7 % increase of AHF-RH risk at
5 years by each unit increase of hFABP of 10 ng/ml.
Conclusions: Combining hFABP plus NT-proBNP (<300 ng/l) only improves diagnostic specificity and PPV to rule out
AHF. hFABP may improve prognosis for long-term AHF-RH, whereas TnI may improve prognosis for ACM.
Trial registration: ClinicalTrials.gov identifier: NCT00143793.
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Background
Human heart-type fatty acid binding protein (hFABP) is
a 15 kDa small protein consisting of 132 amino acids
[1]. It belongs to the FABP superfamily being character-
ized by relative tissue specificity [2]. hFABP is located
primarily in the heart constituting 5–15 % of the cyto-
solic protein pool [3] and is assigned to transport fatty
acids towards the mitochondria for ß-oxidation and en-
ergy expenditure [3–5]. Moreover it protects against free
radical accumulation during myocardial ischemia [6–8]
and influences signal transduction pathways for gene ex-
pression via peroxisome proliferator-activated receptors
(PPAR) [9]. In healthy humans the normal range of
hFABP in serum or plasma has been reported to vary be-
tween 0.0 and 5.5 ng/ml [10, 11]. Fatty acids represent
the main source of energy in the heart accounting for
10 % of the total body turnover of fatty acids [4, 12–14].
The diagnostic value of hFABP has comprehensively
been evaluated in patients suffering from acute myocardial
infarction (AMI). Here, varying diagnostic area under the
receiver-operating characteristic (ROC) curves and diag-
nostic goodness criteria (such as sensitives, specifities,
positive and negative predictive values (NPV/PPV)) have
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been reported for hFABP measurements [15, 16]. Accord-
ingly, combining hFABP with cardiac troponins revealed
conflicting results [17–22]. In contrast, low specifities and
PPVs have been reported for NT-proBNP to reliably diag-
nose acute heart failure (AHF). Therefore new biomarkers
are increasingly focussed to improve both the diagnostic
and prognostic assessement of AHF patients [23, 24].
hFABP was shown to be associated with chronic heart fail-
ure patients (CHF), whereas minor reports indicate a diag-
nostic role of hFABP in children developing concomitant
acute heart failure (AHF) during pneumonia [25–28].
However, hFABP levels have never been primarily evalu-
ated in patients suspected of AHF.
The present study evaluates the diagnostic and long
term prognostic value of additional hFABP measure-
ments compared to NT-proBNP and TnI in patients
presenting with symptoms of acute dyspnea or periph-
eral edema to the emergency department.
Methods
Study patients, design and data collection
The present study represents a post hoc analysis of a spe-
cimen repository from patients enrolled in the Mannheim
NT-proBNP Study (MANPRO, clinicaltrials.gov identifier:
NCT00143793) [29], which was conducted as a single-
centre prospective controlled study at the University
Medical Centre Mannheim (UMM), Germany. The study
was carried out according to the principles of the declar-
ation of Helsinki and was approved by the medical ethics
commission II of the Medical Faculty Mannheim, University
of Heidelberg, Germany. Informed consent was obtained
from all participating patients or their legal representatives.
Briefly, patients with symptoms of acute dyspnea and/or
peripheral edema presenting to the emergency department
were consecutively included from August 2005 until
March 2006 and the underlying diseases such as AHF
were diagnosed. Patients suffering from severe renal dis-
ease (defined as serum creatinine level greater than
2.8 mg/dl), anemia (hemoglobin concentrations below
8.0 g/dl), obvious traumatic causes of dyspnea, pregnancy,
with a status after immediate cardiopulmonary resuscita-
tion, participation in another clinical trial and patients
with age under 18 years were excluded [29, 30].
Diagnosis of acute heart failure
The investigators of the study were neither involved in
therapeutic decisions nor in decisions regarding clinical
examinations. To determine the main diagnosis of each
patient, an independent study physician had unrestricted
access to the records of the patients, but was blinded to
the results of the biomarker measurements. Based on this
approach all patients were classified into two categories:
1) Symptomatic patients because of AHF, 2) symptomatic
patients due to any cause except for AHF.
Diagnosis of AHF was based on European Guidelines
for the diagnosis of AHF [31, 32]. AHF diagnosis being a
decompensated CHF or de-novo AHF, was based on the
acute development of typical symptoms. Additionally,
specific clinical signs made AHF diagnosis even more
favourable, such as pulmonary rales, elevated jugular
venous pressure or hepatojugular reflux. At least one of
the following technical findings substantiated the diag-
nosis of AHF, such as radiographic evidence of pulmon-
ary congestion and edema, abnormalities on the ECG
(i.e. supraventricular tachycardia, ventricular arrhyth-
mias, myocardial ischemia or infarction) or evidence of
left ventricular (LV) systolic dysfunction (defined as
LVEF <55 %) or diastolic dysfunction as assessed by
echocardiography (see below). Patients not fulfilling
AHF criteria were collected in the “no AHF” group.
Diagnoses were not based on biomarker levels (such as
hFABP or NT-proBNP) because patients and physicians
were blinded to biomarker results.
Severity of symptoms were classified according to the
functional New York Heart Association (NYHA) classifi-
cation and structural ABCD classification of the American
College of Cardiology/American Heart Association
[31, 33]. Standard two-dimensional and colour Doppler
imaging was performed by independent cardiologists
during routine clinical care [30]. Parameters of LV systolic
function comprised LV ejection fraction (Simpson’s bi-
plane) (LVEF) and fractional shortening by parasternal
M-mode. A LVEF of <55 % was defined as LV systolic
dysfunction. Diastolic function was routinely assessed
by the E/A ratio during sinus rhythm (the ratio of the
maximum velocities of early (E) to atrial (A) LV filling
determined by pulsed-wave Doppler of the mitral
valve), deceleration time, isovolumetric relaxation time
and ratio of E/E’ (which is used to estimate an increase in
LV diastolic pressure, measured at the basal septum). Defi-
nitions of diastolic dysfunction corresponded to E/E’ >15
or stages 1, 2 and 3 [34].
Measurements of hFABP, NT-proBNP and troponin I
All samples were obtained by venipuncture into serum
and ammonium heparin tubes for biomarker measure-
ments, immediately at presentation to the emergency
department. Within 30 min all blood samples were cen-
trifuged at 2000 g for 10 min. Plasma was separated, ali-
quoted, frozen and stored at −80 °C.
hFABP was measured in serum, NT-proBNP and
troponin I (TnI) were measured in ammonium heparin
plasma in all 401 patients. hFABP measurement was per-
formed with a commercially available immunoassay/
ELISA (hFABP ELISA Catalog Number EA-0305, Signosis
Inc., Sunnyvale, USA) [35]. hFABP was shown to be a
stable protein even after repeated freezing and thawing
[36]. NT-proBNP measurement was performed with a
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commercially available immunoassay on the Dimension®
RxL clinical chemistry system (Flex reagent cartridge
PBNP, Dimension System, Dade Behring Ltd., Atterbury
Milton Keynes, United Kingdom) as previously described
[29]. Contemporary sensitive TnI was measured with the
SIEMENS Dimension® Vista intelligent lab system for
contemporary sensitive cardiac troponin I testing. The
lowest detection limit of the assay is 0.015 ng/ml. The
99th percentile measured at a healthy reference popula-
tion is 0.045 ng/ml with a coefficient of variation (CV)
of 10 % [37].
Study endpoints
The first endpoint tested was whether the diagnostic
value of combined hFABP plus NT-proBNP was com-
parable to NT-proBNP alone for diagnosis of AHF.
The second endpoint was to test the prognostic value
of hFABP in patients admitted to the emergency depart-
ment with symptoms of acute dyspnea and/or edema.
Two prognostic outcomes were considered: all-cause
mortality and AHF-related rehospitalization at 1 and
5 years.
Follow-up was performed in three successive steps:
Firstly, our in-hospital electronic records were screened
with regard to in-hospital all-cause mortality, AHF-
related rehospitalization and last medical contact in our
clinic over a follow-up period of at least 5 years. Sec-
ondly, family physicians of those patients with incom-
plete follow-up after step 1 (i.e. either patients without
any re-admission or patients re-admitted for the last
time before expiration of total 5 years follow-up) were
contacted to complete survival status. Thirdly, survival
status was completed by individual telephone visits with
the remaining patients, who did not complete total
5 years follow-up after follow-up steps 1 and 2.
Statistical methods
For normally distributed data, the Student t test was ap-
plied. Otherwise, the Mann–Whitney U test was used as
nonparametric test. Deviations from a Gaussian distribu-
tion were tested by the Kolmogorov-Smirnov test.
hFABP and NT-proBNP data were log10 transformed,
thereby promoting normality, and the unpaired t-test
was applied. Spearman’s rank correlation for nonpara-
metric data was used to test the association of hFABP
blood levels with clinical parameters. Qualitative param-
eters were analyzed by use of a 2 × 2 contingency table
and Chi2 test or Fisher’s exact test as appropriate. Quan-
titative data are presented as mean ± standard error of
mean (SEM) or as median and interquartile range (IQR),
depending on the distribution of the data. For qualitative
parameters absolute and relative frequencies are pre-
sented. All analyses were exploratory and utilized a
p value of 0.05 (2 tailed) for significance.
Diagnostic value of combined hFABP plus NT-proBNP
versus NT-proBNP alone
1) C-statistics: Receiver-operating characteristic curve
(ROC) analyses with areas under the curves (AUC) were
calculated for diagnosis of AHF. Two logistic regression
models with AHF as dependent variable and the com-
bined biomarkers hFABP plus NT-proBNP as well as
NT-proBNP alone (reference biomarker) as independent
variables were analyzed. The two areas under the ROC
curves were compared using the method by Hanley [38].
The optimal cutoff for the combined biomarkers
accorded to the probabilities being associated with
hFABP and NT-proBNP to suffer from AHF as assessed
by logistic regression models and was chosen where the
Youden index (sensitivity + specificity − 1) yielded max-
imum values. Optimal cutoffs of single NT-proBNP
measurements (i.e. reference) accorded to <300 pg/ml to
“rule out AHF”, as well as to “rule-in AHF” according to
age-dependent cutoff levels of 450 ng/l (age <50 years),
900 ng/l (50–75 years), and 1800 ng/l (>75 years) [24].
Contingency tables were used to assess the individual
diagnostic goodness criteria (i.e. accuracy, specificity, sen-
sitivity, negative/positive predictive values (NPV/PPV)).
Statistical accuracy was defined as the sum of true posi-
tives plus true negatives devided by the number of total
measurements (n = 401). Accuracy, specificity, sensitivity
were compared by McNemar tests.
Prognostic value of hFABP versus troponin I
Kaplan Meyer curves according to hFABP quartiles were
created and the corresponding hazard ratios (HRs) were
calculated for each hFABP quartile in all patients for the
two mentionend prognostic outcomes at 1 and 5 years (i.e.
all cause mortality and AHF related rehospitalization).
Prognostic models were performed using Cox regres-
sion analyses including the following 12 variables to a
reference model [39]: age, sex, left ventricular function,
serum creatinine (mg/dl), NYHA functional class, pres-
ence of diabetes mellitus, the degree of coronary artery
disease, haemoglobin (g/dl), serum sodium (mmol/l),
beta-blocker treatment, angiotensin-converting enzyme
inhibitor or angiotensin II receptor blocker treatment
(ACEI/ARB) and logNT-proBNP levels. Variables of the
reference model were chosen either because of univari-
ate significant associations or because of commonly
known prognostic effects [23, 39].
The biomarkers of interest, hFABP and troponin I,
were subsequently added to this reference model as con-
tinuous variables.
To test whether the inclusion of hFABP and troponin
I valuably improves prognosis of the reference model for
all-cause mortality and AHF related rehospitalization,
different established measurements of model perform-
ance were applied [23, 39–41].
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Statistical measures of discrimination comprised C-
statistics. C-statistics of models with additional hFABP
or troponin I were compared using the Mann–Whitney
U test. Statistical measures of model calibration com-
prise Hosmer-Lemeshow test, Bayesian information cri-
terion (BIC), Akaike information criterion (AIK) and
the Brier score. The global goodness of fit of the models
was evaluated by likelihood ratio tests. Statistical measures
of reclassification comprise integrated discrimination im-
provement (IDI) and net reclassification improvement
(NRI) following Pencina [42].
In Cox regression models an increase of hazard ratio
(HR) correspond to the logarithmic function of NT-
proBNP (ng/l), hFABP per every 10 ng/ml and TnI per
every μg/l change.
The calculations were performed with InStat and
StatMate (GraphPad Software), SPSS software (SPSS
Software GmbH), and SAS (SAS Institute Inc. Cary,
NC, USA).
Results
Associations of hFABP levels with clinical parameters
Baseline characteristics of 401 study patients are summa-
rized in Table 1. hFABP levels were able to differentiate
patients with AHF (median = 28.8 ng/ml, IQR 20.3–
48.1 ng/ml, n = 122) from those without (median =
16.9 ng/ml, IQR 7.2–24.4 ng/ml, n = 279) (p = 0.0001)
(Fig. 1). hFABP levels were higher in NYHA class III/IV
patients compared to NYHA class I/II patients (NYHA
III/IV: median = 27.5 ng/ml, IQR 18.8–48.0 ng/ml, n = 128;
NYHA I/II: median = 19.1 ng/ml, IQR 3.6–25.5 ng/ml,
n = 70) (p = 0.0001) (Fig. 2, left) and higher in ACC/
AHA class C/D patients compared to class A/B patients
(class D/E: median = 22.6 ng/ml, IQR 13.8–39.2 ng/ml,
Table 1 Baseline characteristics of 401 patients initially presenting with acute dyspnea or peripheral edema
Variables All patients No AHF AHF p value*
(n = 401) (n = 279) (n = 122)
Demographics
Age, mean (range) 67 (18–96) 65 (18–96) 73 (36–96) 0.0001
Male, n (%) 205 (51) 131 (47) 74 (61) 0.7
Cardiovascular risk factors, n (%)
Arterial hypertension 268 (67) 170 (61) 98 (80) 0.0001
Hypercholesterinemia 122 (30) 207 (74) 72 (59) 0.003
Cardiac family history 132 (33) 97 (35) 35 (27) 0.3
Smoking 206 (51) 148 (53) 58 (48) 0.3
Diabetes mellitus 120 (30) 67 (24) 53 (43) 0.0001
Main diagnoses, n (%)
Chronic CHF 143 (36) 63 (23) 80 (66) 0.0001
Atrial fibrillation 90 (22) 40 (14) 50 (41) 0.0001
Coronary artery disease 130 (32) 73 (26) 57 (47) 0.0001
Prior myocardial Infarction 89 (22) 47 (17) 42 (34) 0.0002
Valvular heart disease 118 (29) 48 (17) 70 (57) 0.0001
Acute exacerbated COPD 31 (8) 27 (10) 4 (3) 0.03
Acute exacerbated asthma 7 (2) 7 (3) 0 (0) 0.1
Pneumonia 20 (5) 19 (7) 1 (1) 0.01
Pulmonary embolism 12 (3) 12 (4) 0 (0) 0.02
Chronic kidney disease 71 (17) 30 (11) 41 (34) 0.0001
Cancer 19 (5) 19 (7) 0 (0) 0.001
Stroke 10 (2) 8 (3) 2 (2) 0.7
LV EF (%), median (interquartile range) 41 (30–52) 50 (40–58) 39 (27–50) 0.04
Symptoms and signs, n (%)
Peripheral edema 46 (11) 42 (15) 4 (3) 0.02
Dyspnea 235 (59) 183 (66) 52 (42) 0.0001
Both peripheral edema and dyspnea 120 (30) 54 (19) 66 (54) 0.0001
*p values for the comparison between AHF and no AHF group
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n = 215; class A/B: median = 18.1 ng/ml, IQ range 9.8–
25.1 ng/ml, n = 132) (p = 0.0001) (Fig. 2, right). Patients
with LV dysfunction being assessed by echocardiog-
raphy (i.e. LVEF <55 %) had significantly higher levels of
hFABP than patients with regular heart function (me-
dian = 27.0 ng/ml, IQR 17.3–50.9, n = 91 versus 19.2 ng/
ml, 11.1–28.2, n = 135) (p = 0.0001). hFABP levels corre-
lated significantly (p < 0.05) with several indices of car-
diac function being assessed by echocardiography, such
as fractional shortening (r = −0.20), E/A (r = 0.23), left
atrial diameter (r = 0.29), LV enddiastolic diameter (r =
0.34) and LV endsystolic diameter (r = 0.29). hFABP
serum levels correlated significantly (p < 0.05) with cre-
atinine (r = 0.22), hemoglobin (r = −0.13), NT-proBNP
(r = 0.32) and TnI levels (r = 0.23).
Diagnostic value of hFABP in combination with NT-proBNP
The AUC for the combined biomarkers hFABP plus NT-
proBNP was equal to the AUC of NT-proBNP alone
(hFABP plus NT-proBNP, AUC: 0.85; 95 % CI 0.79–0.87;
NT-proBNP, AUC: 0.85; 95 % CI 0.81–0.89; AUC differ-
ence 0.0; p > 0.05), demonstrating that both AUCs valu-
able disriminate AHF patients from no AHF patients.
The AUC of hFABP alone for diagnosis of AHF was 0.72
(95 % CI 0.67–0.78, p = 0.0001).
Combining hFABP plus NT-proBNP compared to single
NT-proBNP at the “rule out AHF” cutoff of <300 ng/l re-
vealed a significant increase in specificity, statistical accur-
acy and PPV (p = 0.0001): specificity (combined: 71 %,
95 % CI 66–77 %; NT-proBNP alone: 48 %, 95 % CI 42–
54 %), PPV (combined: 58 %, 95 % CI 51–65 %; NT-
proBNP alone: 45 %, 95 % CI 39–51 %), statistical accuracy
(combined: 77 %, 95 % CI 73–81 %; NT-proBNP alone:
63 %, 95 % CI 58–68 %). Sensitivity (combined: 89 %,
95 % CI 84–95 %; NT-proBNP: 96 %, 95 % CI 92–99 %)
and NPV (combined: 94 %, 95 % CI 91–97 %; NT-
proBNP: 96 %, 95 % CI 93–99 %) were slightly de-
creased (at least 7 %).
Evaluation of hFABP plus NT-proBNP compared to
NT-proBNP alone according to age-dependent cutoff
levels to “rule-in AHF” (450 ng/l (age <50 years),
900 ng/l (50–75 years), and 1800 ng/l (>75 years)) did
not reveal any improvements neither in AUC’s, sensitiv-
ities, specificities, statistical accuracy nor predictive
values (data not shown).
Prognostic value of hFABP compared to troponin I
Non-survivors (n = 57) had a median hFABP value of
28.6 ng/ml (IQR 16.2–49.1 ng/ml) vs. 19.0 ng/ml (IQR
10.7–28.3 ng/ml) in survivors (p = 0.0009) at 1 year, and
26.2 pg/ml (IQR 16.2–44.9) in non-survivors (n = 129)
vs. 17.8 ng/ml (IQR 10.3–24.9 ng/ml) in survivors at
5 years respectively (p = 0.0001). Patients being rehospita-
lized because of AHF had significantly higher hFABP
levels than patients not being rehospitalized (1 year: AHF
related rehospitalization, n = 34, median = 39.7 ng/ml
(IQR 23.8–77.2 ng/ml), no AHF related rehospitalization,
n = 367, median = 27.5 ng/ml (IQR 18.2–47.2 ng/ml), p =
0.0001; 5 years: AHF related rehospitalization, n = 73, me-
dian = 27.5 ng/ml (IQR 18.2–47.2 ng/ml), no AHF related
rehospitalization, n = 328, median = 18.9 ng/ml (IQR
10.2–28.3 ng/ml), p = 0.0001).
Kaplan Meier survival analyses
Kaplan Meier survival curves illustrate increasing risk of
all-cause death at 1 and 5 years according to quartiles of
Fig. 1 hFABP levels were significantly higher in patients suffering
from acute heart failure (AHF) (n = 122) compared to those without
(n = 279) (p = 0.0001). Data are presented as medians with 25th and
75th percentiles (boxes) and 5th and 95th percentiles (whiskers)
Fig. 2 hFABP levels were significantly higher in patients of
functional NYHA class III/IV (n = 128) compared to those of NYHA
class I/II (n= 70) (p= 0.01) (left) and higher in patients of structural
AHA/ACC stage C/D (n= 215) compared to those of stage A/B (n= 132)
(p= 0.0001) (right). Data are presented as medians with 25th and 75th
percentiles (boxes) and 5th and 95th percentiles (whiskers)
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hFABP. Patients with highest hFABP levels of the 4th
quartile were up to 2.5 times more likely to die within
follow-up periods (range of HRs: 2.1–2.5; p = 0.04)
(Fig. 3, top). Additionally, patients with highest hFABP
levels of the 4th quartile were up to 8.3 times more likely
to be rehospitalized because of AHF within follow up pe-
riods (range of HRs 2.8–8.3, p = 0.001) (Fig. 3, bottom).
Performance metrics of prognostic models
Discrimination
Table 2 shows univariable associations of all variables
with the prognostic outcomes. Either hFABP or TnI
were adjusted in multivariable prognostic models relative
to conventional assessment including 11 risk factors plus
NT-proBNP. All-cause mortality and AHF related rehos-
pitalization were significantly discriminated by including
hFABP or TnI either in all (n = 401) or in AHF patients
(n = 122), as indicated by individual significant AUCs
above 0.7 (p = 0.0001, referring to each individual model)
(Figs. 4 & 5).
When compared to the reference model, prognostic
models including TnI revealed only numerically greatest,
but not significantly different AUCs for all-cause mortal-
ity when applied in all (n = 401) as well as in AHF pa-
tients (n = 122) at 1 and 5 years (highlighted in blue,
Figs. 4 & 5, top).
Accordingly, prognostic models including hFABP re-
vealed only numerically greatest, but not significantly
different AUCs for AHF-related rehospitalization when
applied in all and AHF patients at 1 and 5 years (excep-
tion in all patients at 5 years) (highlighted in blue,
Figs. 4 & 5, bottom).
Calibration and reclassification
All-cause mortality was best calibrated in prognostic
models including TnI (except all-cause mortality at
1 years in all patients). These models revealed favourable
measures of calibration (such as Hosmer Lemshow, Brier
Score, AIC, BIC and likelihood ratios) as well as benefi-
cial NRIs (Figs. 4 & 5, top, highlighted in blue). AHF re-
lated rehospitalization was best calibrated in prognostic
models including hFABP measurements. These models re-
vealed favourable measures of calibration, such as Hosmer
Lemshow, Brier Score, AIC, BIC and likelihood ratios as
Fig. 3 Kaplan-Meier curves evaluated by quartiles of hFABP after 1 (left panel) and 5 (right panel) years of follow-up in the total study cohort
(n = 401). Increasing hFABP levels were significantly associated with long term all-cause mortality (a, top) and AHF related rehospitalization
(b, bottom). Hazard Ratios (HR) were calculated for each risk group according to hFABP quartiles
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well as beneficial NRIs (Figs. 4 and 5, bottom,
highlighted in blue). In contrast, IDIs mostly revealed
only low values and indicated none or insubstantial in-
tegrative improvements.
Cox regression analyses
Multivariate prognostic Cox proportional hazard
models, incorporating the same 12 risk factors as de-
scribed above, revealed up to 2 % increase of all-cause
mortality risk at 5 years alongside with increasing hFABP
levels of 10 ng/ml being initially measured only once in
the emergency department in all patients (HR 1.020;
95 % CI 1.020–0.998; statistical trend p < 0.1) (Table 3).
In contrast, increasing TnI levels of 1 μg/l were not as-
sociated with an increased risk of all-cause mortality
(p > 0.1) (Tables 3 and 4).
Accordingly, Cox models revealed up to 3–7 % in-
crease of AHF related rehospitalization risk at 5 years
alongside with increasing hFABP levels of 10 ng/ml (all
patients: HR 1.034; 95 % CI 1.001–0.068; p = 0.047; AHF
patients: HR 1.073; 95 % CI 1.018–0.132; p = 0.008). In
contrast, increasing TnI levels of 1 μg/l were not associ-
ated with an increased risk of AHF related rehospitaliza-
tion (Tables 3 and 4).
Discussion
This post-hoc analysis of the MANPRO study evaluated
the diagnostic and long-term prognostic values of
hFABP levels in comparison to NT-proBNP and TnI in
patients presenting to the emergency department with
acute dyspnea and peripheral edema being suspected of
acute heart failure (AHF). To the best of our knowledge,
the present analysis is the first investigating the diagnos-
tic and prognostic value of hFABP measurements in
patients being suspected of AHF.
hFABP levels were able to differentiate AHF from
other causes of dyspnea and/or edema, were associated
with higher disease stages of CHF and correlated signifi-
cantly with several indices of cardiac function being
assessed by echocardiography. Combining hFABP with
NT-proBNP increased specificity, statistical accuracy
and PPV when compared to the age-independent cutoff
of single NT-proBNP <300 pg/ml to “rule-out AHF”.
Secondly, highest hFABP levels measured initially in the
emergency department were associated with all-cause
mortality and AHF related rehospitalization at 1 and
5 years as assessed by Kaplan-Meyer analyses. Within
multivariate adjustment in prognostic models containing
11 conventional prognostic risk factors plus NT-proBNP,
all-cause mortality was better characterized in terms of
statistical calibration and reclassification by addition-
ally including TnI. In contrast, AHF-related rehospital-
ization was better characterized in multivariate models
including hFABP.
In the context of heart failure syndromes, hFABP has
mostly been evaluated in studies including adolescent
patients suffering from CHF, thereby commonly focusing
on the prognostic value of hFABP to predict both mortal-
ity and adverse cardiac events [43–45]. In contrast, in-
creasing hFABP levels were shown to be associated with
the severity of heart failure in children with chronic endo-
cardial fibroelastosis or dilated cardiomyopathy [25]. Add-
itionally it has been demonstrated that hFABP was even
more sensitive than brain natriuretic peptide (BNP) to de-
tect the development of secondary AHF in children
primarily suffering from pneumonia [28].
The present study focused on the improvement of the
weaknesses of the age-independent cutoff value of NT-
proBNP <300 ng/l to “rule out AHF”, such as the low
specificity, accuracy and PPV [29]. As recently published
for the presented study cohort [29], the NT-proBNP cut-
off to “rule out AHF” was set at <300 ng/l with a corre-
sponding sensitivity of 96 %, specificity of 48 %, PPV of
45 % and a NPV of 96 %.
As demonstrated in this study, increasing the specifi-
city by additional hFABP measurements might detect
even more patients as “no AHF”, who truly do not suffer
from AHF although presenting with dyspnea and/or per-
ipheral in the emergency department. In contrast, add-
itional hFABP measurements were not shown to reveal
any improvements when applied for age-dependant NT-
proBNP cutoffs to “rule in AHF” [24].
The usefulness of hFABP as a biomarker for the de-
tection of AHF is mainly driven by the molecule’s
Table 2 Significance (p values) of univariate associations of
prognostic variables for all-cause mortality and AHF related
rehospitalization in all patients (n = 401)
All-cause mortality AHF related
rehospitalization
1 year 5 years 1 year 5 years
Sex 0.7174 0.9621 0.4660 0.9865
Age 0.0001* 0.0001* 0.0007* 0.0001*
Diabetes 0.9756 0.3776 0.0030* 0.0001*
Left ventricular function 0.0088* 0.0002* 0.0001* 0.0001*
NYHA class 0.2061 0.0029* 0.0001* 0.0001*
Coronary artery disease 0.5443 0.4715 0.0203* 0.0001*
Beta blocker 0.9888 0.9876 0.0965 0.0008*
ACE inhibitor 0.6988 0.2305 0.0002* 0.0001*
Hemoglobin 0.0001* 0.0001* 0.0182* 0.1096
Creatinine 0.0554 0.0032* 0.0001* 0.0001*
Sodium 0.0661* 0.0099* 0.3777 0.7839
NTproBNP 0.0001* 0.0001* 0.0001* 0.0001*
hFABP 0.0008* 0.0001* 0.0001* 0.0001*
Troponin I 0.0009* 0.0001* 0.0001* 0.0002*
*Level of significance, p < 0.05
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biochemistry and pathophysiological behavior during
myocardial injury. With a molecular size of 15 kDa
hFABP is a small cytosolic protein, being highly present
in the myocardium compared to skeletal muscle [4]. Be-
sides this relative tissue specificity, hFABP is rapidly re-
leased into the serum within 2 h after myocardial injury,
whereas it is usually not present in serum under healthy
conditions. The development of acute heart failure is facil-
itated by myocardial ischemia and necrosis, cardiomyocyte
damage from inflammatory cytokines, oxidative stress or
apoptosis, thereby increasing the permeability of the car-
diomyocyte membrane with consecutive release of cyto-
solic proteins [31, 46]. These conditions might also be the
main stimulus for hFABP serum release in AHF [5, 10].
Therefore measurements of hFABP might be worth to be
tested in a setting of patients being suspected of acute
heart failure [31].
It is assumed that hospitalization because of recurrent
AHF occurs in up to 30 % of heart failure patients
within 90 % days post-discharge [47] and therefore has
a major impact on the health care system. Conflicting
data are available about the effectiveness of discharge
planning, disease management programs and tele-
monitoring in heart failure patients, whereas it remains
unclear, whether AHF readmissions are preventable and
do necessarily indicate a suboptimal standard of care
[47]. Yet the economic benefit implementing hFABP
into clinical risk stratification has not been evaluated at
Fig. 4 Performance of models for all-cause mortality (top) and AHF-related rehopitalization (bottom) at 1 and 5 years in all patients (n = 401)
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all. Additional costs due to the implementation of a new
prognostic biomarkers can only be justified by an im-
provement of clinical outcomes themselves [23, 48, 49].
Based on our findings, the prognostic value of hFABP
next to troponin I and NT-proBNP testing might iden-
tify those patients with an increased risk of upcoming
AHF related rehospitalization or death. Within the present
study, it was demonstrated that prognosis of all-cause
mortality was better reclassified according to improved
net reclassification improvements (NRI) due to additional
measurements of TnI. Interestingly, patients without a fu-
ture AHF related rehospitalization were more correctly re-
classified due to additional measurements of hFABP. Each
unit increase of hFABP by 10 ng/ml being measured only
once in the emergency department was associated with a
2 % increase of all-cause mortality and 3–7 % increase of
AHF related rehospitalization risk at 5 years. All prognostic
models were calculated to current state-of-the-art statistics
in order to receive valuable generalizing results [23, 39–41].
Therefore, our findings might help to further improve
risk stratification of patients being suspected of AHF in
order to reduce heart failure related mortality, readmis-
sions and possibly health care costs after an initial emer-
gency presentation and in-hospital treatment because of
AHF [47, 48, 50, 51].
Study limitations
The present study was conducted as a post-hoc non-
randomized single-center study. The primary inclusion
criteria have been patients presenting with acute dyspnea
Fig. 5 Performance of models for all-cause mortality (top) and AHF-related rehopitalization (bottom) at 1 and 5 years in AHF patients (n = 122)
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Table 3 Multivariable Cox Regression analyses for all-cause mortality and AHF related rehospitalization at 5 years in all
patients (n = 401)
All-cause mortality AHF-related reospitalization
hFABP Troponin I hFABP Troponin I
HR 95 % CI p Value HR 95 % CI p Value HR 95 % CI p Value HR 95 % CI p Value
Age 1.033 1.016–1.050 0.001 1.036 1.019–1.054 0.001 1.012 0.989–1.034 0.301 1.012 0.989–1.034 0.296
Sex 1.261 0.844–1.884 0.259 1.193 0.788–1.804 0.405 1.012 0.593–1.726 0.966 0.989 0.574–1.705 0.968
NYHA functional class 1.107 0.826–1.485 0.496 1.091 0.816–1.458 0.556 1.799 1.257–2.576 0.001 1.765 1.236–2.519 0.002
Left ventricular function 1.227 0.964–1.562 0.096 1.267 0.993–1.616 0.057 1.013 0.756–1.359 0.930 0.995 0.745–1.329 0.973
Coronary artery disease 0.843 0.555–1.280 0.422 0.907 0.595–1.380 0.648 1.438 0.824–2.509 0.201 1.469 0.839–2.569 0.178
Diabetes mellitus 1.194 0.798–1.786 0.389 1.113 0.747–1.660 0.598 1.757 1.056–2.924 0.030 1.623 0.979–2.693 0.061
Creatinine (mg/dl) 0.783 0.470–1.305 0.348 0.849 0.515–1.398 0.519 0.797 0.414–1.533 0.496 0.859 0.451–1.636 0.643
Sodium (mmol/l) 0.974 0.939–1.011 0.160 0.976 0.941–1.012 0.183 1.039 0.978–1.104 0.212 1.039 0.978–1.103 0.218
Hemoglobin (g/dl) 0.860 0.776–0.954 0.005 0.868 0.782–0.962 0.007 1.000 0.874–1.145 0.997 0.996 0.870–1.141 0.957
ACEI / ARB treatment 0.707 0.478–1.045 0.082 0.714 0.484–1.052 0.089 1.647 0.969–2.799 0.066 1.651 0.967–2.820 0.066
Beta-blocker treatment 0.844 0.559–1.275 0.421 0.853 0.567–1.282 0.443 1.066 0.629–1.805 0.813 1.044 0.616–1.769 0.873
LogNT-proBNP (ng/l) 1.445 1.254–1.665 0.001 1.525 1.325–1.755 0.001 1.209 0.993–1.472 0.058 1.251 1.027–1.523 0.026
hFABP (10 ng/ml) 1.020 1.020–0.998 0.081 - - - 1.034 1.001–1.069 0.047 - - -
Troponin I (μg/l) - - - 0.857 0.696–1.057 0.148 - - - 0.982 0.914–1.055 0.620
The logarithmic function of NT-proBNP and hFABP per every 10 ng/ml change were used in Cox Models. Significant p values (p<0.05) are written in bold type.
Dashes indicate non applicable
HR hazard ratio, CI confidence interval
Table 4 Multivariable Cox Regression analyses for all-cause mortality and AHF related rehospitalization at 5 years in AHF
patients (n = 122)
All-cause mortality AHF-related reospitalization
hFABP Troponin I hFABP Troponin I
HR 95 % CI p Value HR 95 % CI p Value HR 95 % CI p Value HR 95 % CI p Value
Age 1.056 1.025–1.088 0.001 1.060 1.029–1.092 0.001 1.027 0.997–1.058 0.079 1.032 1.002–1.062 0.039
Sex 1.096 0.573–2.098 0.783 0.657 0.317–1.362 0.259 1.354 0.651–2.815 0.418 1.548 0.742–3.230 0.244
NYHA functional class 0.942 0.619–1.433 0.780 0.501 0.075–3.333 0.475 1.610 1.001–2.592 0.049 0.798 0.059–10.61 0.864
Left ventricular function 1.263 0.926–1.724 0.141 1.450 1.040–2.021 0.028 1.227 0.875–1.720 0.236 1.167 0.836–1.628 0.364
Coronary artery disease 0.812 0.423–1.561 0.532 0.893 0.461–1.727 0.736 1.140 0.559–2.323 0.718 1.133 0.558–2.302 0.731
Diabetes mellitus 1.163 0.622–2.178 0.635 1.172 0.625–2.198 0.620 1.324 0.682–2.570 0.408 1.202 0.623–2.317 0.584
Creatinine (mg/dl) 0.952 0.463–1.954 0.892 1.234 0.597–2.547 0.571 0.400 0.159–1.003 0.051 0.448 0.187–1.073 0.072
Sodium (mmol/l) 0.978 0.920–1.039 0.463 0.967 0.910–1.026 0.264 1.113 1.023–1.211 0.013 1.123 1.030–1.225 0.008
Hemoglobin (g/dl) 0.836 0.701–0.998 0.047 0.827 0.694–0.986 0.034 0.949 0.792–1.139 0.576 0.934 0.780–1.117 0.453
ACEI/ARB treatment 0.919 0.498–1.701 0.790 1.005 0.544–1.859 0.987 1.425 0.722–2.812 0.307 1.501 0.758–2.974 0.244
Beta-blocker treatment 0.895 0.488–1.644 0.721 0.826 0.451–1.511 0.535 1.387 0.704–2.732 0.345 1.550 0.795–3.023 0.198
LogNT-proBNP (ng/l) 1.207 0.911–1.601 0.190 1.324 0.997–1.757 0.052 0.911 0.696–1.192 0.496 1.015 0.780–1.320 0.912
hFABP (10 ng/ml) 0.996 0.948–1.047 0.873 - - - 1.073 1.018–1.132 0.008 - - -
Troponin I (μg/l) - - - 0.789 0.567–1.071 0.125 - - - 0.982 0.914–1.055 0.620
The logarithmic function of NT-proBNP and hFABP per every 10 ng/ml change were used in Cox Models. Significant p values (p<0.05) are written in bold type.
Dashes indicate non applicable
HR hazard ratio, CI confidence interval
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and/or peripheral edema to the emergency department.
AHF diagnosis was only made by one independent cardi-
ologist as stated, while a triple panelist approach might
have further increased the validity of AHF diagnosis [29].
Initial medical heart failure treatment (e.g. by nitrates and
diuretics) might have influenced hemodynamic changes,
the relief of clinical symptoms and heart function over
time. Evaluable echocardiographic examinations were
available in 210 of 401 patients with a median of 3 days
after the inital emergency department presentation [30].
Assessment of hFABP performance in patients with
HFpEF versus HFrEF has been beyond the scope of the
present analysis. Patients with a history of cerebro-
vascular diseases (CVA or TIA) and atrial fibrillation were
not excluded and might have influenced the range of
hFABP levels. Cardiovascular mortality was not evaluated
as a prognostic outcome in the present trial. Only index-
hospital AHF-related rehospitalization was assessed. Com-
peting AHF related rehospitalization at other hospitals
was not evaluated. Prognostic event rates might have been
under-estimated and might not reflect the complete clin-
ical reality. Evaluating our results with ultra-sensitive
troponin methods may allow better diagnostic and prog-
nostic results compared to the contemporary TnI assay
being used in this study. Notably, hFABP was measured by
a manual, not standardized immunoassay, which might be
time consuming and not cost effective in current clinical
practice, as there is no automated bedside test currently
available on the market. The diagnostic and prognostic
values of hFABP, as well as its standardized and cost-
effective measurement need to be confirmed by ongoing
medical research within larger prospective clinical studies
with AHF patients specifically taking into account the
above mentioned limitations.
Conclusions
Taken together, this post-hoc analysis demonstrates that (1)
additional hFABP measurements improved diagnostic spe-
cificity of sole NT-proBNP testing at the cutoff <300 ng/l
to “rule out” AHF. (2) In prognostic models containing 11
conventional risk factors plus NT-proBNP, hFABP mostly
improved prognostic models for AHF-related rehospitaliza-
tion at 1 and 5 years, whereas troponin I mostly improved
prognostic models for all-cause mortality.
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